IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Authors :: Emery, P.
Keystone, E.
Tony, H.P.
Cantagrel, A.
van Vollenhoven, R.
Sanchez, A.
Alecock, E.
Lee, J.
Kremer, J.
Source :: Annals of the Rheumatic Diseases. Nov, 2008, Vol. 67 Issue 11, p1516, 8 p.
Publication Year :: 2008

Subjects :: Rheumatoid arthritis -- Patient outcomes
Rheumatoid arthritis -- Research
Interleukin-6 -- Physiological aspects
Health

Tools